Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents

References

• Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 2014;24:33-40
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol 2010;20:46-53
   PubMed Web of Science ®Google Scholar
• Tanaka E, Hoshi D, Igarashi A, et al. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA Modern Rheumatology 2013;23:742-51
   PubMed Web of Science ®Google Scholar
• Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006;44:304-10
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
   PubMed Web of Science ®Google Scholar
• Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84
   PubMedGoogle Scholar
• Furuya H, Kasama T, Isozaki T, et al. Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidiscip Healthc 2013;6:25-30
   PubMedGoogle Scholar
• Kim G, Barner JC, Rascati K, et al. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis. J Manag Care Spec Pharm 2015;21:401-7
   PubMed Web of Science ®Google Scholar
• DeWitt EM, Lin L, Glick HA, et al. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther 2009;31:1871-80
   PubMed Web of Science ®Google Scholar
• Yelin E, Tonner C, Kim SC, et al. Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. Arthritis Care Res 2014;66:980-9
   Google Scholar
• Saokaew S, Sugimoto T, Kamae I, et al. Healthcare databases in Thailand and Japan: potential sources for health technology assessment research. PLoS One 2015;10:e0141993
   PubMed Web of Science ®Google Scholar
• Charlson, ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Radner H, Smolen J, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:536-41
   PubMed Web of Science ®Google Scholar
• Nakajima A, Inoue E, Shimizu Y, et al. Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol 2015;34:441-9
   PubMed Web of Science ®Google Scholar
• Kvien TK, Uhlig T, Ødegård S, et al. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann NY Acad Sci 2006;1069:212-22
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007;17:28-32
   PubMedGoogle Scholar
• Forslind K, Hafstrom I, Ahlmen M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66:46-52
   PubMed Web of Science ®Google Scholar
• Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3
   PubMed Web of Science ®Google Scholar
• Katada H, Yukawa N, Urushihara H, et al. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. Clin Rheumatol 2015;34:949-95
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Rabidou N, Dhar D. Are rheumatologists’ treatment decisions influenced by patients’ age? Rheumatology 2006;45:1555-7
   PubMed Web of Science ®Google Scholar
• Radovits BJ, Fransen J, Eijsbouts A, et al. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:906-10
   PubMed Web of Science ®Google Scholar
• Kievit W, van Hulst L, van Riel P, et al. Factors that influence rheumatologists’ decision to escalate care in RA: results from a choice based conjoint analysis. Arthritis Care Res 2010;62:842-7
   Web of Science ®Google Scholar
• Curtis J, Singh J. The use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Therapeut 2001;33:679-707
   Web of Science ®Google Scholar
• Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Carpenter L, Norton S, et al. Different levels of moderate disease in rheumatoid arthritis are associated with varying risk for joint destruction and failure: time to update DAS cut-offs for biologic DMARD use? EULAR 2015: Abstract OP179
   Google Scholar
• Reynolds A, Koenig AS, Bananis E, et al. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoeconomics Outcomes Res 2012;12:319-33
   PubMed Web of Science ®Google Scholar
• Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 2012;4:3-9
   PubMedGoogle Scholar
• Blake T, Rao V, Hashmi T, et al. The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice. BMC Musculoskelet Disord 2014;15:290
   PubMed Web of Science ®Google Scholar